Literature DB >> 14638657

Nefazodone (Serzone) withdrawn because of hepatotoxicity.

Stephen Choi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14638657      PMCID： PMC264962     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  4 in total

1.  Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions.

Authors:  Olav Spigset; Staffan Hägg; Andrew Bate
Journal:  Int Clin Psychopharmacol       Date:  2003-05       Impact factor: 1.659

Review 2.  Diagnosis and management of depression in primary care: a clinical update and review.

Authors:  Ronald A Remick
Journal:  CMAJ       Date:  2002-11-26       Impact factor: 8.262

Review 3.  SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression.

Authors:  J M Kent
Journal:  Lancet       Date:  2000-03-11       Impact factor: 79.321

4.  Hepatic adverse reactions associated with nefazodone.

Authors:  Donna E Stewart
Journal:  Can J Psychiatry       Date:  2002-05       Impact factor: 4.356
  4 in total
  11 in total

Review 1.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2010-06-10       Impact factor: 4.849

2.  Incomplete patient drug information still a problem.

Authors:  Sana R Sukkari; Larry D Sasich
Journal:  CMAJ       Date:  2004-11-09       Impact factor: 8.262

3.  Psychiatric care of the patient with hepatitis C: a review of the literature.

Authors:  Muhamad Aly Rifai; Ondria C Gleason; Douha Sabouni
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

4.  Major depressive disorder in hepatitis C: an open-label trial of escitalopram.

Authors:  Ondria C Gleason; William R Yates; Michelle A Philipsen
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

5.  Comparing Machine Learning Algorithms for Predicting Drug-Induced Liver Injury (DILI).

Authors:  Eni Minerali; Daniel H Foil; Kimberley M Zorn; Thomas R Lane; Sean Ekins
Journal:  Mol Pharm       Date:  2020-06-08       Impact factor: 4.939

6.  Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study.

Authors:  Ondria C Gleason; John C Fucci; William R Yates; Michelle A Philipsen
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

7.  Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.

Authors:  Adjia Hamadjida; Stephen G Nuara; Dominique Bédard; Imane Frouni; Cynthia Kwan; Jim C Gourdon; Philippe Huot
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-07       Impact factor: 3.000

Review 8.  Antidepressants in long-term migraine prevention.

Authors:  Horst J Koch; Tim P Jürgens
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions.

Authors:  Sabine U Vorrink; Yitian Zhou; Magnus Ingelman-Sundberg; Volker M Lauschke
Journal:  Toxicol Sci       Date:  2018-06-01       Impact factor: 4.849

Review 10.  Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man.

Authors:  Sanja Dragovic; Nico P E Vermeulen; Helga H Gerets; Philip G Hewitt; Magnus Ingelman-Sundberg; B Kevin Park; Satu Juhila; Jan Snoeys; Richard J Weaver
Journal:  Arch Toxicol       Date:  2016-09-22       Impact factor: 5.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.